Market Intelligence for Glioblastoma CAR-T, Solid Tumor ADCs, and Fibrosis-Targeted Modalities.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-13RA2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-13RA2 ECD-Fc Fusion Protein / Mutant Protein High purity (>95%), Endotoxin <1 EU/μg, Sequence Verified, HEK293 Expressed (Native Glycosylation), Theoretical MW confirmed. |
View IL-13RA2 Products |
| Gene Delivery | IL-13RA2 Promise-ORF / Lentivirus Premade Particles Full-length ORF (NM_000640) for stable cell line generation. Preserves native conformation for flow cytometry and internalization assays. |
View IL-13RA2 Products |
| Benchmark Ab | Anti-IL-13RA2 (Clinical Lead Sequence) Recombinant positive control for binding, ELISA, and specificity assays. |
View IL-13RA2 Products |
| Validator | IL-13RA2 siRNA Set (3 unique sequences) For knockdown verification and target-specificity controls in cell-based assays. |
View IL-13RA2 Products |
| Ligand | IL-13 (Interleukin-13) Primary cognate ligand for binding competition and affinity characterization. |
View IL-13 Products |
| Counter Screen | IL-13RA1 (IL-13 Receptor Alpha 1) Signaling homolog receptor for selectivity profiling, off-target assessment, and reverse screening. |
View IL-13RA1 Products |
| Related Target | EGFRvIII Synergistic target for dual-antigen CAR-T strategies in Glioblastoma (GBM). |
View EGFRvIII Products |
| Pathway Partner | IL-4Rα (CD124) Shared subunit of the Type II IL-4/IL-13 receptor complex; critical for off-target safety assessment. |
View IL-4Rα Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform & Homolog Selectivity (IL-13RA1 vs IL-13RA2) | Homolog panel (IL-13RA1, IL-13RA2) strictly verified by Mass Spec; Low cross-reactivity risk. Human IL-13RA1 and IL-13RA2 proteins available with >95% purity for counter-screening. |
| Cross-species Cyno/Mouse efficacy evaluation | Human/Cyno/Mouse IL-13RA2 ortholog proteins available; Sequence Verified; >95% Purity; Endotoxin Controlled. |
| Receptor Conformation for ADCs & CAR-T | HEK293 Expressed (Native Glycosylation) ECD-Fc formats for accurate internalization assays; Lentivirus-based stable cell lines preserving native membrane conformation. |
| Ligand Blockade vs Non-Blockade Epitope Mapping | High-affinity IL-13RA2 ECD-Fc for SPR/BLI competition assays with IL-13. |
| Lack of Controls & Assay Standardization | Clinical Benchmark Antibodies included as positive controls for binding and functional assays. |
| False Positives due to Non-Specific Binding | Validated siRNA (3 unique sequences) included for strict specificity checks in cell-based assays. |
Live IL-13RA2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of IL-13RA2 is intensifying, with major players shifting focus from traditional mAbs to Chimeric Antigen Receptor T-cell (CAR-T) therapies and Antibody-Drug Conjugates (ADCs). IL-13RA2 is highly overexpressed in glioblastoma multiforme (GBM) and other solid tumors (e.g., ovarian, melanoma) while exhibiting restricted expression in normal tissues, making it an ideal tumor-associated antigen. Simultaneously, a bifurcating paradigm is emerging: engineered cellular therapies exploit its overexpression in oncology, while antibody-based modalities (blocking mAbs, decoy receptor fusions) target the IL-13 decoy pathway in idiopathic pulmonary fibrosis (IPF) and liver fibrosis. The unique decoy function of IL-13RA2—binding IL-13 with high affinity but lacking signaling motifs—demands rigorous assay validation. As first-generation CAR-T constructs face antigen escape and soluble receptor shedding, next-generation logic-gated receptors and conditionally activated ADCs are entering preclinical development.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| CAR-T Cell Therapy | City of Hope, Mustang Bio, Duke University, UNC Lineberger | Glioblastoma Multiforme (GBM) | Stable cell line generation (Lentivirus) for target validation; Internalization kinetics; Cytotoxicity assays; Receptor binding with natively glycosylated ECD. |
| ADC | Medicenna, Various Biotechs | Solid Tumors (Ovarian, Melanoma) | High-purity ECD-Fc for conjugation optimization; Internalization assay using full-length cell surface target. |
| Targeted Immunotoxin | NIH, Various Academic | Refractory GBM | Selectivity assay (need counter-screening against IL-13RA1). |
| Blocking Monoclonal Antibody | Mid-stage Fibrosis Biotechs | Idiopathic Pulmonary Fibrosis (IPF) | Ligand competition assay (vs IL-13 binding); Selectivity panel against IL-13RA1. |
| Decoy Receptor Fusion (Agonist) | Preclinical Startups | Liver Fibrosis, NASH | Soluble IL-13RA2 ECD-Fc as therapeutic template; Binding affinity validation by SPR. |